BioThrax | Anthrax Vaccine Adsorbed

Protection through prevention

BioThrax | Anthrax Vaccine Adsorbed
Learn
BioThrax is the only FDA-licensed vaccine available for pre-exposure protection against anthrax infection.
Learn
According to the Centers for Disease Control and Prevention (CDC), weaponized anthrax is one of the greatest possible threats to the public.
Learn
BioThrax is for the active immunization of adults at high risk of exposure to anthrax.
This product information is intended only for the residents of the United States.

The most common (≥10%) local (injection-site) adverse reactions observed in clinical studies were tenderness, pain, erythema, edema, and arm motion limitation. The most common (≥5%) systemic adverse reactions were muscle aches, headache, and fatigue. Acute allergic reactions, including anaphylaxis, have occurred with BioThrax.

Vaccination with BioThrax should be avoided by individuals with a history of anaphylactic or anaphylactic-like reaction following a previous dose of BioThrax or any component of the vaccine.

If BioThrax is used during pregnancy, or if the patient becomes pregnant during the immunization series, the patient should be apprised of the potential hazard to the fetus. Pregnant women should not be vaccinated unless the potential benefits of vaccination have been determined to outweigh the potential risk to the fetus. It is not known whether BioThrax is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when BioThrax is administered to a nursing woman.

BioThrax should be administered with caution to persons with a possible history of latex sensitivity since the vial stopper contains dry natural rubber.